Immunotherapy before surgery for DNA-mismatch repair colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can shrink or eliminate colon tumors in people with dMMR/MSI-high cancer, possibly allowing some to avoid surgery. It is for patients whose cancer has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with colon or upper rectal cancer that has not spread to other organs.
- Your tumor must have a specific DNA repair deficiency called 'dMMR' or high microsatellite instability (MSI-high).
- You need to be in good enough health to undergo surgery and possibly chemotherapy.
- You must have normal organ function and no history of autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and porustobart) given before surgery for colon cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial tests whether using a simple blood test (ctDNA) can help guide treatment with immunotherapy drugs (PD-1 inhibitors) for people with a specific type of colon cancer (MSI-high/dMMR). The goal is to see if this approach can improve outcomes and reduce side effects compared to standard care.
This study tests whether an immunotherapy drug called tislelizumab can help prevent colon cancer from coming back after surgery. It is for people with a specific genetic feature (dMMR) in their tumor, which may make the treatment more effective.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This study tests dostarlimab given before surgery for stage II or III colon cancer that has a specific DNA repair defect. It aims to shrink or control the cancer so that some people may be able to skip surgery if the results are good.
This study tests giving an immunotherapy drug (pembrolizumab) before surgery for people with early-stage colon cancer that has a specific genetic feature. The goal is to see if the drug can shrink the tumor enough to avoid more extensive surgery.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.